We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
Read MoreHide Full Article
On Mar 18, we issued an updated research report on Inogen, Inc. (INGN - Free Report) . A strong fourth-quarter show and solid prospects in Europe currently favor the stock. On the contrary, trade-related uncertainties plague this Zacks Rank #3 (Hold) company.
What’s Favoring the Stock?
In the recently-reported fourth quarter of 2018, Inogen posted earnings of 44 cents per share, which surpassed the Zacks Consensus Estimate of 25 cents. The bottom line improved from a net loss of 3 cents in the year-ago quarter.
Revenues came in at $86.5 million, which trumped the Zacks Consensus Estimate of $82 million. On a year-over-year basis, the top line climbed 35.7%.
Reflective of this, Inogen retained its revenue and EBITDA outlook for 2019.
Notably, the company continues to expect revenues between $430 million and $440 million, representing 20.1-22.9% growth over 2018.
Full-year adjusted EBITDA is projected between $67 million and $71 million, representing 9.3-15.9% growth year over year.
Moreover, Inogen is optimistic about its prospects in Europe.
In the fourth quarter of 2018, Inogen’s business-to-business unit saw international revenues of $18.5 million, up 54.5% year over year on continued adoption by the company’s European partners. Per management, Europe sales represented 87.8% of fourth-quarter international sales.
Deterrents
Despite a better-than-expected fourth quarter, Inogen trimmed its 2019 net income guidance range to $40-$44 million from the previously-issued $48-$52 million. Per management, the slashed guidance is due to a fall in estimated provision for income taxes related to excess tax benefits recognized from stock-based compensation.
Additionally, the company’s guidance assumes a full impact of the tariffs on applicable Chinese sourced materials since the increase of China import tax has been currently delayed by the United States, giving rise to trade-related uncertainties.
Price Performance
Over the past year, shares of Inogen have declined 23.5% against the industry’s 9.8% gain. The current level is also lower than the S&P 500 index’s 4.3% rally.
Penumbra’s long-term earnings growth rate is expected at 20.9%.
Wright Medical’s long-term earnings growth rate is estimated at 11.3%.
DexCom’s next-quarter earnings per share are projected to grow 120%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
On Mar 18, we issued an updated research report on Inogen, Inc. (INGN - Free Report) . A strong fourth-quarter show and solid prospects in Europe currently favor the stock. On the contrary, trade-related uncertainties plague this Zacks Rank #3 (Hold) company.
What’s Favoring the Stock?
In the recently-reported fourth quarter of 2018, Inogen posted earnings of 44 cents per share, which surpassed the Zacks Consensus Estimate of 25 cents. The bottom line improved from a net loss of 3 cents in the year-ago quarter.
Revenues came in at $86.5 million, which trumped the Zacks Consensus Estimate of $82 million. On a year-over-year basis, the top line climbed 35.7%.
Reflective of this, Inogen retained its revenue and EBITDA outlook for 2019.
Notably, the company continues to expect revenues between $430 million and $440 million, representing 20.1-22.9% growth over 2018.
Full-year adjusted EBITDA is projected between $67 million and $71 million, representing 9.3-15.9% growth year over year.
Moreover, Inogen is optimistic about its prospects in Europe.
In the fourth quarter of 2018, Inogen’s business-to-business unit saw international revenues of $18.5 million, up 54.5% year over year on continued adoption by the company’s European partners. Per management, Europe sales represented 87.8% of fourth-quarter international sales.
Deterrents
Despite a better-than-expected fourth quarter, Inogen trimmed its 2019 net income guidance range to $40-$44 million from the previously-issued $48-$52 million. Per management, the slashed guidance is due to a fall in estimated provision for income taxes related to excess tax benefits recognized from stock-based compensation.
Additionally, the company’s guidance assumes a full impact of the tariffs on applicable Chinese sourced materials since the increase of China import tax has been currently delayed by the United States, giving rise to trade-related uncertainties.
Price Performance
Over the past year, shares of Inogen have declined 23.5% against the industry’s 9.8% gain. The current level is also lower than the S&P 500 index’s 4.3% rally.
Key Picks
A few better-ranked stocks in the broader medical space are Penumbra, Inc. (PEN - Free Report) , Wright Medical Group N.V. and DexCom. Inc. (DXCM - Free Report) . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s long-term earnings growth rate is expected at 20.9%.
Wright Medical’s long-term earnings growth rate is estimated at 11.3%.
DexCom’s next-quarter earnings per share are projected to grow 120%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>